Neurorehabilitation News

ORLANDO — Adjunctive treatment with brivaracetam led to significant seizure reduction and seizure freedom in a cohort of adults with focal onset epilepsy, according to interim results of a study.

The FDA has conferred with BrainStorm Cell Therapeutics Inc. regarding NurOwn, an investigational technology platform developed to treat amyotrophic lateral sclerosis.

ORLANDO — Shipping medication and equipment to health care professionals for those with epilepsy in crisis zones such as Ukraine to allow for continuity of care requires a multidisciplinary effort, according to a speaker.

ORLANDO — Patients with seizures who were given point-of-care electroencephalography had shorter time to initiation and shorter hospital stays compared with those given conventional EEG, according to research.

ORLANDO — In cognitively healthy adults, the presence of seizures predicted earlier change from normal cognition to mild cognitive impairment but was not associated with change from MCI to dementia. according to research.

The FDA has cleared a traumatic brain injury blood test for commercial availability, paving the way for its distribution to hospitals in the United States.

A decrease of incidence and proportion of concussions resulted from implementation of a rule in the National Hockey League forbidding hits to the head, researchers reported in JAMA Network Open.

The FDA has issued a warning against the purchase or use of products that contain tianeptine, which has been illegally sold with claims to improve brain function and treat anxiety, depression, pain, opioid use disorder and other conditions.

A Boston-area biopharmaceutical has announced additional positive biomarker data from a phase 1/2a study of a novel cancer vaccine immunotherapeutic intended to treat those with recurrent glioblastoma.

A Boston-area biopharma company announced positive data from a phase 1a/b trial of a novel therapeutic to treat newly diagnosed glioblastoma multiforme, resulting in the initiation of a first-line phase 2b study.